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Background: Invasive meningococcal disease (IMD) incidence in Germany is low, but management of contacts to
prevent subsequent cases still requires resources. Local public health authorities (LHA) advise antibiotic post-exposure
prophylaxis (PEP) and vaccination to close contacts as defined in national guidance. We aimed to audit implementation
of recommendations for IMD public health management in the state of Baden-Wuerttemberg, Germany, and to estimate
associated costs.
Methods: We surveyed all 38 LHAs in Baden-Wuerttemberg to evaluate knowledge of national guidance and
implementation of IMD contact management using standardized questionnaires. For IMD cases notified in
2012, we requested numbers of household and other contacts ascertained, including advice given regarding
PEP and post-exposure vaccination, plus staff time required for their management. We estimated costs for advised
antibiotics, LHA staff time and visits to emergency departments according to published sources. The cost of preventing
a subsequent case was estimated based on the number of household contacts that received PEP per IMD case and on
the previous finding that ~284 household contacts must receive PEP to prevent one subsequent IMD case.
Results: Although LHAs were familiar with national recommendations, they did not advise PEP to 4% of household
contacts, while 72% and 100% of school and health provider contacts, respectively, were advised PEP. Only 25% of
household contacts of a case with a vaccine-preventable serogroup were advised post-exposure vaccination. A mean
of 11.0 contacts/IMD case (range 0–51), of which 3.6 were household contacts, were recommended PEP. Per IMD case,
mean costs for LHA staff were estimated at €440.86, for antibiotics at €219.14 and for emergency department visits to
obtain PEP at €161.70 - a total of €821.17/IMD case. Preventing a subsequent IMD case would cost ~ €65,000.
Conclusions: Our results provide insight into costs of IMD public health management in Germany. We identified
marked underuse of post-exposure vaccination in household contacts and overuse of PEP in school and health care
contacts. In view of an estimated 3–6 quality-adjusted life years lost per case of IMD, our estimated cost of €65,000 for
preventing a subsequent case seems justifiable.
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Invasive meningococcal disease (IMD), caused by Neisseria
meningitidis, manifests most commonly as meningitis or
sepsis [1]. The incidence in Germany decreased in recent
years, from 0.95 to 0.44 IMD cases/100,000 inhabitants,
and similar decreases were observed in other European
countries [2]. Nonetheless, even a single case can generate
substantial public concern [3] because of high case fatality,
propensity to affect the young and occasional appearance
in clusters [4]. Modelling studies [5,6] estimated that 3–6
quality adjusted life years could be gained per case averted.
Provision of antibiotic post-exposure prophylaxis (PEP)
and, in case of a vaccine-preventable strain in the index
case, post-exposure vaccination of defined contacts, are
evidence-based measures to reduce the risk of subsequent
IMD cases [7]. Household contacts of persons with IMD
have a higher risk of acquiring the disease [8,9]. This also
holds for close contacts in preschool settings, albeit to a
lesser extent [10]. For household settings, the European
Centre for Disease Prevention and Control (ECDC) esti-
mated the number of contacts needed to be treated (NNT)
with PEP to prevent one case at 284 (95% confidence
interval (CI): 156–1515) [7]. For pre-school settings,
NNT was estimated at 1998 (95% CI: 1307–4259).
Much larger numbers of contacts would require treatment
in school and university settings to prevent one IMD case
[7]. By far, PEP provided to household contacts, who face
the highest risk, contributes most to the prevention of
subsequent cases. According to guidance of Standing
Committee on vaccination and the Robert Koch-
Institute (RKI) [11,12], the following persons are de-
fined as close contacts of an IMD index case: 1) all
household members, 2) contacts in the same group of
an index case in kindergarten/pre-schools with children
under six years, 3) household-like contacts, such as
persons living in the same dormitory or military bar-
racks as an index case, 4) persons with contact to oro-
pharyngeal secretions of an index case, e.g. sexual
partner, close friends, school contacts seated next to an
index case, 5) medical staff if exposed to oropharyngeal
secretions of an index case, e.g. through mouth-to-
mouth resuscitation or unprotected intubation.
In Germany, IMD is statutorily notifiable by both physi-
cians and laboratories. Cases are notified to local public
health authorities (LHA) and forwarded to the state public
health authorities according to a standardized case defin-
ition [13]. Surveillance data suggest that the case fatality of
IMD is 8% [14].
The German Protection Against Infection Act requires
local health authorities to implement measures to pre-
vent further transmission of infectious diseases [15].
LHAs trace and manage contacts of cases with IMD
according to guidance provided by the national public
health institute, the Robert Koch Institute (RKI) [12],based on STIKO recommendations [11]. STIKO rec-
ommends PEP with an antibiotic that eradicates men-
ingococcal carriage for close contacts of an IMD index
case. Recommended antibiotics for children are rifam-
picin (20 mg/kg/b.i.d. for 2 days except 10 mg/kg/ b.i.d. for
2 days for newborns) or intramuscular (i.m.) ceftriaxone
(125 mg. for < 12 year-olds, 250 mg i.m. for ≥12 year-olds),
ciprofloxacin (500 mg single dose) or rifampicin (600 mg
bi.d. for 2 days) for adults and ceftriaxone (250 mg i.m.) for
pregnant women [11]. Post-exposure vaccination is recom-
mended for household (-like) contacts if the IMD index
case is diagnosed with a vaccine-preventable serogroup (in
2012: A, C, W, Y). Guidance on management of invasive
meningococcal disease is also made available by the Na-
tional Reference Laboratory for Meningococci in Wuerz-
burg [16], the German Society for Paediatric Infectious
Diseases [17], the Working Group Meningococci of the
German Green Cross for Health [18] and in a handbook
on infectious diseases by Littmann et al. [19]. In December
2013, a new vaccine licensed to protect against serogroup
B meningococci was made available on the European mar-
ket. RKI and STIKO planned to model the impact of im-
plementation of this meningococcal B vaccine. However,
evidence on costs of public health management of spor-
adic IMD in Germany or other countries was lacking at
the time this study was launched. A systematic review was
available on the cost of managing IMD outbreaks [20], in-
cluding implementation of chemoprophylaxis and targeted
vaccination. Costs ranged from $2,000-56,000 (≈€1,600-
45,000) per one IMD case [20], depending on the size and
location (high or low income country) of the outbreaks.
We performed an audit of the implementation of national
recommendations for public health management of IMD
in the federal state of Baden-Wuerttemberg, Southwest
Germany, with a population of 10.5 million. Our objective
was to evaluate knowledge of national guidance in LHAs
and to describe actual implementation of management of
contacts of sporadic IMD to estimate associated costs.Methods
Cross-sectional study on knowledge and awareness of
national recommendations for IMD contact management
In May 2013, we surveyed head physicians of all 38
LHAs in Baden-Wuerttemberg regarding usual prac-
tices applied in each LHA for public health manage-
ment of notified IMD cases. We sent a questionnaire to
collect information on use of available guidance docu-
ments for public health management of IMD, criteria
applied to define and identify contact persons for PEP
or post exposure vaccination and the number of staff
available for public health management of infectious
diseases.
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In a second questionnaire, we asked the head physicians of
LHAs that had notified one or more IMD cases in 2012 to
provide information on the number and types of contacts
identified for each case notified in 2012, and whether PEP
or post-exposure vaccination had been advised. In addition,
the questionnaire collected information on the number and
working hours of physicians and other staff involved in the
management of each notified case.
Cost identification
We used the results from the cross sectional study to
identify the antibiotics advised by LHAs for PEP in chil-
dren, adults and pregnant women. We estimated the pro-
portion of pregnant women among adult contact persons
based on population census and live births data for Baden-
Wuerttemberg [21].
Medications
We estimated the cost of antibiotics advised to contacts
of notified cases using the German medical formulary
for 2014 [22]. We used the price for the smallest unit
provided by the manufacturer – the lowest possible
number of tablets or the lowest possible volume of oral
liquid formula purchasable and sufficient to treat one
person. The cost of the smallest units of antibiotics rec-
ommended for PEP in tablet form were as follows:
€39.47 for blister of ten splittable 600 mg rifampicin tab-
lets, €14.36 for a blister of fourteen 500 mg ciprofloxacin
tablets and €5.36 for a single i.m. dose of ceftriaxone.
The cost of the smallest unit of rifampicin syrup, 100 ml
containing 1.2 g of rifampicin, was €21.60.
Health care delivery
As physicians can bill for only one patient visit per quarter
(i.e. 4 times per year), we did not include costs for office
visits to obtain PEP. We assumed that most contacts
would see their doctor in the current quarter for other
reasons. However, we included visits to emergency ser-
vices, estimated at €30 each according to a survey of emer-
gency departments [23].
Staff cost
We estimated the cost of full-time equivalent (FTE) staff
involved in management of the contacts based on re-
muneration according to the civil service pay scale, as
published by the Association of Municipal Employer
associations (VKA) in 2014 [24]. We calculated daily
wages based on annual wages assuming 230 working
days/year. We assumed that LHA physicians were paid
according to the highest grade of remuneration at level
15 (€290.81/day), hygiene inspectors according to the
highest grade of remuneration at level 8 (€153.11/day)and administrative staff according to the highest grade
of remuneration at level 6 (€140.59/day).
We estimated the number of household contacts who
received PEP per one IMD index case (HC). Taking into
consideration the known NNT (284) to prevent one sub-
sequent case in household settings, contact management
of N cases (N = 284/HC) potentially prevented one sub-
sequent case in household settings. We thus estimated
the approximate cost of preventing one subsequent IMD
case in Baden-Wuerttemberg through public health
management as N*(FTE staff cost + cost of antibiotics +
cost of visit at emergency services).
Data analysis
We entered data in EpiData Entry 3.1. (EpiData Associ-
ation, Odense, Denmark). Analysis was performed using
Excel (Excel 2007, Microsoft Corporation, US) and Stata
12 (Stata Corp, Texas, US). Denominators vary due to
missing responses on the questionnaires.
Ethical approval
The study was based on statutory case notifications of
meningococcal disease to public health authorities in the
federal State of Baden-Wuerttemberg for the year 2012,
as mandated by the German Protection against Infection
Act. These data were available in anonymized form at
the federal state and national levels, i.e. information con-
cerning personal or material circumstances could thus
no longer or only with an incommensurate amount of
effort, time and expense be linked to an identified or
identifiable individual. Ethical approval for analysis of
such surveillance data is not required according to the
Medical Association’s professional code of conduct [25].
The additional data collected in relation to these cases at
the level of the local health authorities did not involve
further information on the patients themselves, but only
aggregated information on their contact management
and associated resources required at the level of the local
health authorities, i.e. the legal status of the data as
anonymized remained unchanged. Thus ethical approval
for performance of this study was not considered necessary.
Results
Implementation of national recommendations for IMD
contact management
Of the 38 LHA, 34 returned the questionnaire (response
89%). All responding LHAs stated they followed national
recommendations to manage IMD contacts. LHAs most
frequently used documents issued by RKI (32/34, 94%)
or STIKO (27/33, 82%), with only one LHA using neither
of these. Three LHAs also used recommendations issued
by the National Reference Laboratory for Meningococci in
Wuerzburg, and one each used recommendations pub-
lished by the German Society for Paediatric Infectious
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Green Cross for Health. Two LHAs also used their own
guidelines and one LHA used a handbook [19].
In line with RKI/STIKO guidance, all LHAs stated
they would advise PEP to all household members of an
IMD case (Table 1). However, 29% of LHAs reported
that they would advise PEP to more contacts than rec-
ommended by RKI/STIKO in kindergarten/preschool
settings, 47% in schools and 32% in healthcare settings
(Table 1).
Of the several antibiotics that LHAs stated advising
for PEP in different age groups, rifampicin was most
often advised for infants, children and adolescents, cip-
rofloxacin for adults, and ceftriaxone i.m. for pregnant
women (Table 2). In terms of the mean number of full
time equivalent (FTE) staff positions available at epi-
demiology departments for public health management of
infectious diseases, the 34 responding LHAs reported
1.6 physicians (range 0.75-3.5), 2.3 hygiene inspectors
(range 0–8) and 1.2 administrative staff (range 0–3).
IMD contact management
In 2012, 27 LHAs notified 49 IMD cases. Twenty-three
LHAs returned questionnaires on 41 IMD cases (84%
response).
The responding LHAs identified 473 contact persons
for these 41 cases, of whom 451 (95%, 324 adults, 127
children) were advised to take PEP for a mean of 11 con-
tacts per index case of IMD (range: 0–51, 3 children andTable 1 Invasive meningococcal disease (IMD) contacts to wh
antibiotic post-exposure chemoprophylaxis (PEP)
Contact category
Household All household members
Kindergarten/preschool All children in the facility
Only the group of index c
Teacher of the index case
School Only pupils sitting in neigh
Class of the index case
Teacher of the index case
Students’ residence or similar (e.g. barracks,
hotels)
All residents
Only residents on the sam
Only residents in the same
Travellers* Contact with oropharynge
Sitting in proximity to inde
Contact longer than a spe
Healthcare workers Any contact with index ca
Only if contact with oroph
case
Survey of 34 Local Health Authorities (LHA), Baden-Wuerttemberg, Germany, 2013.
*Travellers = person travelled in the same airplane, train or bus as the index case.
**Time interval specified between one and eight hours.8 adults). Of these 451 contacts, 148 (33%) were house-
hold members of 33 cases, 83 (18%) medical personnel
of 14 cases, 34 (8%) school children of 4 cases, 3 (0.7%)
fellow residents in a dormitory of 1 case, 73 (16%) family
visitors of 14 cases and 110 (24%) other contacts of 20
cases (Table 3). As age was not specified for family visi-
tors and other contacts, we assumed 50% each were
adults and children < 18 years. The latter consisted
mainly of work colleagues and friends, including con-
tacts at a disco. No case had contacts in a kindergarten/
preschool setting. The proportion of ascertained con-
tacts advised to obtain PEP was high, at 72% in school
contacts and over 95% in all other categories (Table 3).
Of the 41 IMD cases for whom a questionnaire was
returned, 12 were caused by a vaccine-preventable ser-
ogroup (8 C, 1 W and 3 Y), 26 were caused by ser-
ogroup B and the serogroup was unknown in 3 cases.
The 12 cases with a vaccine-preventable serogroup had
a total of 36 household contacts, 9 (25%) of whom were
advised to obtain post-exposure vaccination. Of the 95
household contacts of cases with the then non-vaccine-
preventable serogroup B, 6 (6.3%) were nonetheless ad-
vised to obtain post-exposure vaccination, including one
adolescent. In addition, 20 non-household contacts were
advised to receive post-exposure vaccination, 15 of whom
were contacts of a case with a vaccine-preventable ser-
ogroup. Three persons were living in the same dormitory
as the case, 8 were medical staff, 1 was a school contact
and 3 were other contacts.om local health authority (LHA) would recommend





ase 23 33 70
31 32 97




e floor 13 34 38
room 20 34 59
al secretions of index case 33 33 100
x case 31 32 97
cified time** 9 30 30
se 11 34 32
aryngeal secretions of index 22 34 65
Table 2 Antibiotics recommended by local health authority (LHA) for post-exposure prophylaxis of different categories
of invasive meningococcal disease contacts, Survey of 34 LHA, Baden-Wuerttemberg, Germany, 2013
LHAs recommending antibiotic
Rifampicin Ciprofloxacin Ceftriaxone i.m. Other [which]
Contact category n N % n N % n N % n N %
Infants 28 29 97 1 29 3 - - - 1 30 3 [unspecified]
Toddlers 30 30 100 1* 30 3 2* 30 7 - - -
School children (5–11 years) 30 30 100 5* 30 17 - - - - - -
Adolescents (12–17 years) 28 30 93 4** 30 13 7* 30 23 - - -
Adults 16† 30 53 27 30 90 3‡ 30 10 - - -
Pregnant women 1 30 3 1 30 3 27 30 90 1 30‡‡ 3 [azithromycin]
n = number of LHAs recommending this antibiotic; N = total number of LHAs responding to question; *in addition to rifampicin; **2/4 in addition to rifampicin;
†13/16 in addition to ciprofloxacin, thus 3 (10%) recommended only rifampicin; ‡ in addition to ciprofloxacin; ‡‡in addition to ceftriaxone.
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either through a general practitioner (GP) (all 33contacts
of 5 cases), from a hospital (all 22 contacts of 7 cases) or,
in 27 cases, from a combination of both supply channels
(417 contacts). We assumed that half of the latter obtained
PEP through each of these supply channels, respectively.
Some contacts of 2 cases received antibiotics directly from
the LHA.Costs of IMD contact management
Management of a notified case of sporadic IMD mobi-
lized the majority of physicians, hygiene inspectors and
other administrative personnel assigned to public health
management of infectious diseases at LHAs for 1–2 days
(Table 4). The cost of work of staff at LHAs per one
IMD case amounted €343 for physicians, €54 for hygieneTable 3 Number of contacts and proportion advised post-exp
(LHA) for 41 invasive meningococcal disease (IMD) cases noti





Household members 0–18 years 35 16
Household members >18 years 113 35
Healthcare workers 83 14
Kindergarten/preschool NA 0
School 34 3
Dormitory or similar 3 1
Family visit* 73 14
Children (<19 years) 37 14
Adults (>18 years) 36 14
Other contacts 110 20
Children (<19 years) 21 4
Adults (>18 years) 89 16
A total of 451 contacts, 127 children and 324 adults, were recommended PEP.
NA: Not applicable *As age was not specified, we assumed ~50% each children andinspectors and €44 for administrative staff as derived in
Table 4. The overall estimated total staff cost was €441
per IMD case.
Based on the cross-sectional survey, for adults, 10% of
LHAs advised exclusively rifampicin, 47% exclusively
ciprofloxacin and 43% either rifampicin or ciprofloxacin
(Table 2). As a single-dose regimen of ciprofloxacin is
likely perceived as more convenient, we estimated that only
a minority - 20% - of adult contacts received rifampicin,
79% of adults contacts received ciprofloxacin and 1% of
adult contacts (pregnant women) received ceftriaxone i.m.
We simplified cost estimation for children by assuming that
all children received 100 ml (1.2 g) rifampicin syrup. For
children > 30 kg (≈ > 10 years of age), who would require a
higher dosage, we nonetheless applied the lower price for
1.2 g of the rifampicin syrup, under the assumption that
some children would not receive a separate prescription,
but share PEP antibiotics from a unit prescribed toosure prophylaxis as reported by local health authorities
fied in 2012 in Baden-Wuerttemberg, Germany
ases with
ntact

















Table 4 Staff time required for public health management of an invasive meningococcal disease (IMD) case, survey of
34 local health authorities (LHA), Baden-Wuerttemberg, Germany, 2013
FTE* staff
Mean Range Mean person-days Person-days (range) Staff cost
Physicians 1.58 1-3 1.18 0.12-3.00 €343
Hygiene inspectors 1.00 0-5 0.35 0.12-2.50 €54
Other personnel 1.26 0-2 0.31 0-2.00 €44
Total 3.84 1.84 €441
*FTE = full-time equivalent.
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older children would be prescribed the lower-priced
ciprofloxacin.
Since for each notified IMD case the LHAs advised
PEP to a mean of 3 children and 8 adults, the cost of
PEP per one IMD case was €219 (Table 5).
According to LHA, 49% of contacts received PEP
through emergency services, translating to 5.39 contacts
per case. The cost per one IMD case was thus €162 (=
5.39 *€30).
We thus estimated the total cost of managing the con-
tacts of an IMD case at LHAs at €822 (€441 for
personnel + €219 for antibiotics + €162 to obtain PEP
through emergency services).
In our survey, for each IMD index case, 3.6 household
contacts and 7.4 other contacts received PEP. Taking
into account the NNT for household contacts [7], con-
tact management in Baden-Wuerttemberg prevented
one subsequent case in household settings at a cost of ≈
€65,000 ((284/3.6)*€822).
We made a rough estimate of the cost of recommend-
ing PEP unnecessarily to contacts in the school and
health care setting, although this was limited by the low
number of cases with school contacts. We assumed that
in general no more than 2 school or health care contacts
should receive PEP according to recommendations. In
our study, in 2 cases, 6 and 21 school contacts, and in
10 cases, >2 health care contacts ( a total of 78 contacts)
were recommended PEP, translating to potentially 23
and 58 contacts, respectively, with an unnecessary rec-
ommendation. Subtracting these numbers from the totalTable 5 Estimated average cost of antibiotics for contacts of
















Ceftriaxone i.m. 5.36 1%
Totalnumber of child and adult contacts advised to obtain
PEP according to our survey decreased the number of
child and adult contacts requiring PEP to 2.5 (from 3.0)
and 6.5 (from 8.0) per case, respectively, reducing the
cost estimate per case for antibiotics from €219 to €179
and the costs for emergency services from €162 to €133.
The total costs per case would thus be reduced to €753,
and the cost for preventing a subsequent case to ≈
€59,000.
Discussion
Our results indicated that LHAs in Baden-Wuerttemberg
were aware of the available national recommendations
on public health management of IMD. Almost all used
RKI/STIKO guidance documents. Antibiotics for PEP
advised by LHAs were all in keeping with this guidance.
However, according to the cross-sectional survey,
LHAs tended to advise PEP to a wider circle of contacts
than recommended in the national recommendations.
The retrospective case study also suggested that a sub-
stantial number of contacts without an indication re-
ceived antibiotics, as LHAs advised PEP for 34 of the
47 school contacts and for all 83 health care worker
contacts. On the other hand, a few household contacts
(4%) were not advised to obtain antibiotics, despite all
LHAs having stated that they would, in principle, ad-
vise PEP to all of these.
Only a quarter of household contacts of an index case
with a vaccine-preventable serogroup were advised to re-
ceive post-exposure vaccination. A possible explanation
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availability of information would make further contact
necessary to advise vaccination once serogroup information
becomes available. On the other hand, post-exposure vac-
cination was advised to a number of household contacts
even though the index case was not due to a vaccine-
preventable serogroup. One such contact was of adolescent
age for which meningococcal C vaccine is generally recom-
mended. Some contacts, most notably health care workers,
were advised post-exposure vaccination even though this
was not recommended according to RKI/STIKO guidance.
A high level of anxiety upon the occurrence of IMD cases
and a desire to do everything possible to prevent further oc-
currence of this severe disease, as well as pressure from the
contacts themselves, particularly health care workers, may
explain the tendency to recommend PEP or vaccination to
more contacts than necessary.
Our results indicated that management of the contacts
of an IMD case engaged most members of the LHA in-
fectious disease public health team for 1–2 days, thus
putting a considerable strain on the staff and likely re-
quiring postponement of other public health tasks.
We estimated the cost of preventing a subsequent case
of IMD through public health management of a sporadic
cases of IMD to be ≈ €65,000. Since ≈ 3-6 QALYs are lost
through a case of IMD [5,6], this amounts to ≈ €11,000-
22,000 per QALY gained, or ≈ €10,000-20,000 if PEP
were recommended more judiciously. While the use of
cost-effectiveness thresholds is controversial and has not
been applied for medical or preventive interventions in
Germany thus far, threshold values applied in various
countries or by certain institutions in the past consid-
ered to be cost-effective generally ranged from $20,000
to $100,000 (≈€15,000-80,000) per QALY [26]. Thus, the
seemingly high cost of preventing one IMD case of
€65,000 through contact management according to our
study appears justifiable - also in view of the severity, high
case fatality, and the high treatment costs for acute disease,
complications and sequelae in a high proportion of cases
[27,28]. Furthermore, the cost per IMD case prevented
could be reduced if LHAs limited their advice for PEP to
contacts according to national recommendations.
Our estimate of resources required for public health
management of IMD cases has several limitations. First,
it was based on only 41 cases of IMD from only one fed-
eral state in Germany and these do not mirror the entire
range of possible contact scenarios. For instance, none
of the contacts were infants or children in kindergarten/
preschool. In addition, some contact scenarios applied
only to a very low number of cases. Second, we may have
overestimated the cost for antibiotics, as in rare cases con-
tacts might receive single doses directly in the emergency
department rather than the smallest available blister pack.
However, as we chose the lowest possible price of thesmallest possible quantities, it is also possible that costs
were higher for some individuals. In addition, we did not
include costs for any doctors’ office visits to obtain PEP, al-
though in some cases they may have applied. Finally, we
did not include the costs of post-exposure vaccination.
Overall, these limitations would have led us to under-
estimate the costs for obtaining PEP. Nonetheless, our re-
sults provide insight into the magnitude of costs for public
health management of sporadic IMD in Germany. Since
termination of our study, a British study estimated a
somewhat lower cost for the public health management of
a single IMD case at £317.72 (approximately €400) [29].
However, this was based on an analysis of a single index
case in a cluster of two cases in a primary school. Costs
for management of the two epidemiologically linked cases
were 17-fold higher than management of a primary case,
in keeping with the high costs found for management of
IMD clusters in [20].
Conclusions
The awareness of national recommendations for pub-
lic health management of IMD was high in LHAs of
Baden-Wuerttemberg. However, LHAs advised PEP to
a wider circle of contacts than specified in the recom-
mendations. At the same time, implementation of
post-exposure vaccination among household contacts
with a vaccine-preventable serogroup was markedly
underused. To close this identified knowledge-practice
gap, we encouraged LHAs to limit advice for PEP to
contacts as defined in national recommendations and
to improve implementation of post-exposure vaccin-
ation for household contacts. A better implementation
of the national recommendations would optimize pre-
vention and avoid unnecessary expenses. Finally, our
results provide insight into the costs of public health
management in Germany for the first time and are being
used to parameterize a model to estimate the costs and
benefits of meningococcal B vaccination in Germany.
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